Study cycle definition

Study cycle. Second cycle Subject area: [degree in sending institution] Code: [ISCED-F code] Number of completed higher education study years: Student with: a financial support from EU funds  a zero-grant from EU funds 
Sample 1
Study cycle. [First cycle/ Second cycle/ Third cycle / Short cycle / One-cycle study programme] Subject area: [field of study in sending institution] Code: [ISCED-F code] Study year: The financial support includes: special needs support exceptional needs to support participants with fewer opportunities Bank account the financial support should be paid to: Account number: Account holder (if different than student) Bank name BIC/SWIFT IBAN Currency of the bank account hereafter referred to as “the participant”, of the other part, have agreed the Special conditions and Annexes below which form an integral part of this agreement (“the agreement”): Annex I Learning Agreement for Studies / Learning Agreement for Traineeship / Learning Agreement for Studies and Traineeship Xxxxx XX Certificate of Attendance Xxxxx XXX General Conditions The terms set out in the Special conditions shall take precedence over those set out in the annexes. It is not compulsory to circulate papers with original signatures for Annex I of this document: scanned copies of signatures and electronic signatures may be accepted, depending on the national legislation.
Sample 1Sample 2
Study cycle refers to either bachelor or master and will thus provide these options in the relevant dropdown-menu. • It is particularly tricky to complete the “Field of education” box. Entering the normal programme title will not work. Please use the title as provided in the list you can find here: xxxxx://xxx.xx- xxxxxxxxxx.xx/xxxxxxxxx/xxxx_xxxxxx/xx_xx/Xxxxxxxxx/Xxxxxxx_XXXXX- Codes_Field_of_Education_Zuordnung_zu_den_Fakultaeten.pdf Generating a learning agreement
Sample 1Sample 2

Examples of Study cycle in a sentence

  • For each Interconnection Study within an Interconnection Study Cycle, the CAISO may develop one or more Group Studies.

  • If an Interconnection Customer disputes the withdrawal and removal from the Interconnection Study Cycle and has elected to pursue Dispute Resolution, the Interconnection Customer's Interconnection Request will not be considered in any ongoing Interconnection Study during the Dispute Resolution process.

  • Withdrawal shall result in the removal of the Interconnection Request from the Interconnection Study Cycle.

  • Prior to adoption and publication of final per unit costs for use in the Interconnection Study Cycle, the CAISO shall publish to the CAISO Website draft per unit costs, including non-confidential information regarding the bases therefore, hold a stakeholder meeting to address the draft per unit costs, and permit stakeholders to provide comments on the draft per unit costs.

  • Under all circumstances, an Interconnection Customer that withdraws or is deemed to have withdrawn its Interconnection Request during an Interconnection Study Cycle is obligated to pay to the CAISO all costs in excess of the Interconnection Study Deposit that have been prudently incurred or irrevocably have been committed to be incurred with respect to that Interconnection Request prior to withdrawal.

  • There will be two Cluster Application Windows associated with each Interconnection Study Cycle.

  • Notwithstanding the foregoing, an Interconnection Customer that withdraws or is deemed to have withdrawn its Interconnection Request during an Interconnection Study Cycle shall be obligated to pay to the CAISO all costs in excess of the LGIP Transition Cluster Interconnection Study Deposit that have been prudently incurred or irrevocably have been committed to be incurred with respect to that Interconnection Request prior to withdrawal.

  • Interconnection Requests that have not met the requirements of GIP Section3.5.1 within twenty (20) Business Days after the close of the applicable Cluster Application Window or ten (10) Business Days after the CAISO first provided notice that the Interconnection Request was not valid, whichever is later, will be deemed invalid and will not be included in Interconnection Study Cycle or otherwise studied..

  • The Deliverability Assessment Base Case for the Phase II Interconnection Study will include Option (A) Generating Facilities in the current Interconnection Study Cycle and earlier queued Generating Facilities that will utilize TP Deliverability in a total amount that fully utilizes but does not exceed the available TP Deliverability.

  • Notwithstanding the foregoing, an Interconnection Customer that withdraws or is deemed to have withdrawn its Interconnection Request during an Interconnection Study Cycle shall be obligated to pay to the CAISO all costs in excess of the Interconnection Study Deposit that have been prudently incurred or irrevocably have been committed to be incurred with respect to that Interconnection Request prior to withdrawal.


More Definitions of Study cycle

Study cycle. ☐First cycle ☐Second cycle ☐Third cycle ☐Short cycle ☐One-cycle study programme Cycle d’études : ☐1er cycle ☐2è cycle ☐3è cycle ☐cycle court ☐cycle unique Subject area (degree in sending institution): Domaine d’études (diplôme de l’établissement d’envoi) : ISCED- F Code / Code CITE-F : Number of completed higher education study years: Nombre d’années d’études supérieures achevées : Student with / Le participant sera : ☐ a financial support from Erasmus+ EU funds / allocataire de fonds européens Erasmus+ ☐ a zero-grant / non-allocataire de fonds européens Erasmus+ ☐ a financial support from Erasmus+ EU funds combined with zero-grant / partiellement allocataire de fonds européens Erasmus+. The financial support includes / L’aide financière comprendra : ☐ special needs support / un complément de financement en raison d’une situation de handicap. For all participants receiving financial support from Erasmus+ EU funds, except those receiving ONLY a zero-grant from EU funds: Informations bancaires à compléter pour les participants recevant une aide financière Erasmus+ (ne concerne pas les non-allocataires) : Bank account where the financial support should be paid: Numéro de compte bancaire sur lequel la subvention sera versée : Bank account holder (if different than student): Titulaire du compte (si différent de l’étudiant) : Bank name: Nom de la banque : BIC/SWIFT : IBAN : Called hereafter “the participant”, of the other part / Ci-après dénommé “le participant” d’autre part, Have agreed to the Special Conditions and Annexes below which form an integral part of this agreement ("the agreement"): ont accepté les conditions particulières et annexes ci-dessous, qui font partie intégrante du présent contrat (« le contrat ») : Annex I ☐ Learning Agreement for Erasmus+ mobility for studies / Contrat pédagogique pour les mobilités d’études Annex II ☐ General Conditions / Conditions générales Xxxxx XXX ☐ Erasmus Student Charter / Charte de l’étudiant Erasmus+. The terms set out in the Special Conditions shall take precedence over those set out in the annexes. It is not compulsory to circulate papers with original signatures for Annex I of this document: scanned copies of signatures and electronic signatures may be accepted, depending on the national legislation or institutional regulations. Les conditions particulières prévalent sur les annexes. L’annexe I ne devra pas obligatoirement comporter les signatures originales, les signatures scannées et électroniques étant acc...
Sample 1
Study cycle. [First/Second/Third] Subject area/degree in sending institution: Code: [ISCED-F code, click below] Number of completed higher education study years: ☐ 0313 Applied Psychology ☐ 0210 Art Education, Audiovisual Media Culture, Applied Visual Arts ☐ 0212 Design (Clothing, Graphic, Interior and Textile, Industrial, Service) ☐ 0110 Education ☐ 0421 Law ☐ 0413 Management and Administration ☐ 0312 Political Sciences ☐ 0923 Social Work ☐ 0314 Sociology ☐ 0113 Teacher Training without subject specialisation ☐ 1015 Tourism Research Student with: ☒ A financial support from Erasmus+ EU funds ☐ A zero-grant ☐ A financial support from Erasmus+ EU funds combined with zero-grant The financial support includes: ☐ Special needs support ☐ Financial support to student with children Called hereafter “the participant”, of the other part, Have agreed to the Special Conditions below and Annexes in SoleMOVE mobility system, which form an integral part of this agreement ("the agreement"): Annex I Learning Agreement for Studies Xxxxx XX General Conditions Xxxxx XXX Xxxxxxx Student Charter The terms set out in the Special Conditions shall take precedence over those set out in the annexes.
Sample 1
Study cycle. ☐First cycle ☐Second cycle ☐Third cycle ☐Short cycle ☐One-cycle study programme Home Faculty/School: Name of diploma registered in current academic year in home institution: Title of CIVIS project: Host Institution name: Location of physical mobility (address) Bank account where the financial support should be paid: Bank account holder (if different than student): Bank name: BIC/SWIFT : IBAN : Called hereafter “the participant”, of the other part Have agreed to the Conditions and Annex(es) below which form an integral part of this agreement ("the agreement"): ☐ Annex I: Physical activities’ programme It is not compulsory to circulate papers with original signatures of this document: scanned copies of signatures and electronic signatures may be accepted, depending on the national legislation or institutional regulations.
Sample 1
Study cycle. Bachelor or equivalent first cycle (EQF level 6) / Master or equivalent second cycle (EQF level 7) / Doctorate or equivalent third cycle (EQF level 8). To note: at Imperial College the final year of the MEng or MSci degree would equate to Master.
Sample 1
Study cycle choose your study cycle (at DTU) at the time of the exchange STEP 2: Sending institution: • Choose Denmark and then DTU via the two drop down menus.
Sample 1
Study cycle. [First cycle/Second cycle/Third cycle/long-cycle] Subject area: [degree in sending institution] Code: [ISCED-F code] Number of completed higher education study years: Student with: a financial support from EU funds  a zero-grant from EU funds  a financial support from EU funds for [xxx] days combined with zero-grant from EU funds for [xxx] days  The financial support includes: Special needs support  Financial Support to student having rights to receive a merit-based stipend as defined in the HEI’s internal regulations  [For all participants receiving financial support from EU funds, except those receiving ONLY a zero-grant from EU funds]. Bank account where the financial support should be paid: Bank account holder (if different than student): Bank name: Clearing/BIC/SWIFT number: Account/IBAN number: called hereafter “the participant” of the other part, have agreed the Special Conditions and Annexes below which form an integral part of this agreement ("the agreement"): Annex I [Institution to select: Learning Agreement for Erasmus+ mobility for studies/ Learning Agreement for Erasmus+ mobility for traineeships/Learning Agreement for Erasmus+ mobility for studies and for traineeships] Annex II General Conditions Annex III Erasmus Student Charter The terms set out in the Special Conditions shall take precedence over those set out in the annexes. [It is not compulsory to circulate papers with original signatures for Annex I of this document: scanned copies of signatures and electronic signatures may be accepted, depending on the national legislation.] SPECIAL CONDITIONS
Sample 1

Related to Study cycle

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase I Clinical Trial means a clinical trial conducted in healthy humans or patients, which clinical trial is designed to establish the safety, drug-drug interactions and/or pharmacokinetics of an investigational drug given its intended use, and to support continued testing of such drug in Phase II Clinical Trials.

  • Study Period means the period commencing at 9:00 a.m. on the date hereof, and continuing through 5:00 p.m. on the Closing Date.

  • Phase III Clinical Study means a human clinical study of a product on a sufficient number of subjects that is designed to establish that such product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, as described in 21 C.F.R. 312.21(c). 1.185. [***] 1.186. [***]

  • Phase II Study means a study in humans of the safety, dose ranging or efficacy of a product, as further defined in 21 C.F.R. § 312.21(b) (or the equivalent thereof outside the United States).

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, or Pivotal Study, as applicable; but excluding any Post-Approval Studies.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Feasibility Study means a comprehensive study of a deposit in which all geological, engineering, operating, economic and other relevant factors are considered in sufficient detail that it could reasonably serve as the basis for a final decision by a financial institution to finance the development of the deposit for mineral production;

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Pivotal Study means (a) a Phase 3 Study that is intended by Celgene to be submitted (together with any other registration trials that are prospectively planned when such Phase 3 Study is initiated) for Regulatory Approval in the U.S. or the EU, or (b) any other clinical study that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical study is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for the Licensed Product in the U.S. or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such study.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Phase 3 Study means a clinical study of a drug candidate in human patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Phase III Clinical Trial means a human clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Licensed Product for one or more indications in order to obtain Marketing Approval of such Licensed Product for such indication(s), as further defined in 21 C.F.R. §312.21 or a similar clinical study in a country other than the United States.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.